Dr. Paolo Paoletti, M.D. is the first, appointed president of GSK Oncology. In his role, Dr.Paoletti champions an organisation of more than 800 professionals around the world dedicated to fighting the causes and impacts of cancer. As the leader of the newly formed business unit, Dr. Paoletti has P&L accountability for the overall oncology business within GSK and oversees all the activities from early drug discovery through clinical development, launch and life cycle management. Under Dr. Paoletti’s leadership, GSK Oncology has achieved an almost unprecedented level of success in bringing forth important advances to cancer care with US and EU approvals for Arranon/Atriance; Tykerb/Tyverb; Promacta/Revolade; Arzerra and Votrient. Dr. Paoletti’s team continues to reshape the direction of cancer research by moving into innovative areas such as cancer stem cell research, epigenetics and cancer metabolism. Prior to joining GSK, Dr. Paoletti was the Vice President, Clinical Development for Lilly Oncology, where his team secured indications for Gemzar and Alimta. Dr. Paoletti holds a medical degree from the University of Pisa, Italy, and completed postgraduate studies to receive certification in Pulmonary Diseases and Nuclear Medicine.